drugset / Trial / NCT07529613
Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and tolerability of the combination therapy of T-DXd, nivolumab, and chemotherapy in patients with untreated HER2-low gastric or gastroesophageal junction adenocarcinoma, and to determine the recommended dose. Subsequently, the efficacy and safety at the recommended dose will be assessed.
Timeline
- Start
- 2023-12-20
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 750 mg/m2 | Oral |
| Subject | Nivolumab | Monoclonal antibody | 360 mg | Intravenous |
| Subject | Oxaliplatin | Small molecule | 70 mg/m2 | Intravenous |
| Subject | Trastuzumab deruxtecan | Monoclonal antibody | 4.4 mg/kg | Intravenous |